Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development of iPSC-derived ...

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has begun ...

Marker Therapeutics was awarded a $2 million grant from NIH Small Business Innovation Research Program (SBIR) to support the clinical investigation of MT-601 in patients with lymphoma who have ...

Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...

Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic ...

Syncona said the performance was mostly driven by a decline in Autolus Therapeutics PLC share price and a weaker US dollar, and was partially offset by valuation uplifts from private portfolio company ...

T-cell therapy is a revolutionary immunotherapy approach in which T cells are genetically modified to express a receptor that ...

These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

In the world of cell therapy, Silicon Valley has long recognized that technological innovation is the key to solving ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...